{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T01:02:35Z","timestamp":1768093355158,"version":"3.49.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T00:00:00Z","timestamp":1596758400000},"content-version":"am","delay-in-days":372,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01GM049551"],"award-info":[{"award-number":["R01GM049551"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01AI044616"],"award-info":[{"award-number":["R01AI044616"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"NSF","doi-asserted-by":"publisher","award":["DGE-1122492"],"award-info":[{"award-number":["DGE-1122492"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH F31 fellowship","award":["CA203254"],"award-info":[{"award-number":["CA203254"]}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["F32AI104334"],"award-info":[{"award-number":["F32AI104334"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["T32AI055403"],"award-info":[{"award-number":["T32AI055403"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006132","name":"Office of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"DOE","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006132","name":"Office of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006231","name":"Brookhaven National Laboratory","doi-asserted-by":"publisher","award":["DE-AC02-98CH10886"],"award-info":[{"award-number":["DE-AC02-98CH10886"]}],"id":[{"id":"10.13039\/100006231","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006231","name":"Brookhaven National Laboratory","doi-asserted-by":"publisher","award":["Y181C HIV"],"award-info":[{"award-number":["Y181C HIV"]}],"id":[{"id":"10.13039\/100006231","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008582","name":"McGill University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008582","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.bmcl.2019.06.047","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T12:08:01Z","timestamp":1561550881000},"page":"2182-2188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Molecular and cellular studies evaluating a potent 2-cyanoindolizine catechol diether NNRTI targeting wildtype and Y181C mutant HIV-1 reverse transcriptase"],"prefix":"10.1016","volume":"29","author":[{"given":"Tomoaki","family":"Sasaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zira T.K.","family":"Gannam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9680-4067","authenticated-orcid":false,"given":"Shalley N.","family":"Kudalkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen M.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won-Gil","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krasimir A.","family":"Spasov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William L.","family":"Jorgensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen S.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2019.06.047_b0005","unstructured":"U.J.P.o.H.A. (UNAIDS), 2012 Report on the Global AIDS Epidemic, 2012."},{"key":"10.1016\/j.bmcl.2019.06.047_b0010","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1124\/mi.9.2.5","article-title":"Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets","volume":"9","author":"Adamson","year":"2009","journal-title":"Mol Interventions"},{"key":"10.1016\/j.bmcl.2019.06.047_b0015","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.antiviral.2009.09.009","article-title":"Novel approaches to inhibiting HIV-1 replication","volume":"85","author":"Adamson","year":"2010","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bmcl.2019.06.047_b0020","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1006\/jmbi.1994.1665","article-title":"Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance","volume":"243","author":"Tantillo","year":"1994","journal-title":"J Mol Biol"},{"key":"10.1016\/j.bmcl.2019.06.047_b0025","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1097\/00002030-199910010-00017","article-title":"Natural history of HIV infection in the era of combination antiretroviral therapy","volume":"13","author":"Moore","year":"1999","journal-title":"AIDS (London, England)"},{"key":"10.1016\/j.bmcl.2019.06.047_b0030","doi-asserted-by":"crossref","unstructured":"J.D. Roberts, K. Bebenek, T.A. Kunkel, The accuracy of reverse transcriptase from HIV-1, Science (New York, N.Y.), 242 (1988) 1171\u20131173.","DOI":"10.1126\/science.2460925"},{"key":"10.1016\/j.bmcl.2019.06.047_b0035","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cbdv.200490012","article-title":"Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future","volume":"1","author":"De Clercq","year":"2004","journal-title":"Chem Biodivers"},{"key":"10.1016\/j.bmcl.2019.06.047_b0040","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/373117a0","article-title":"Viral dynamics in human immunodeficiency virus type 1 infection","volume":"373","author":"Wei","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2019.06.047_b0045","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa041305","article-title":"Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy","volume":"351","author":"Jourdain","year":"2004","journal-title":"New Engl J Med"},{"key":"10.1016\/j.bmcl.2019.06.047_b0050","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1128\/AAC.44.9.2475-2484.2000","article-title":"Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy","volume":"44","author":"Bacheler","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2019.06.047_b0055","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1039\/c2cs35058k","article-title":"In search of a treatment for HIV\u2013current therapies and the role of non-nucleoside reverse transcriptase inhibitors","volume":"41","author":"Reynolds","year":"2012","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.bmcl.2019.06.047_b0060","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1128\/AAC.48.12.4680-4686.2004","article-title":"TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1","volume":"48","author":"Andries","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2019.06.047_b0065","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1021\/jm040840e","article-title":"In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine)","volume":"48","author":"Janssen","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.06.047_b0070","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nrd3845","article-title":"Reducing safety-related drug attrition: the use of in vitro pharmacological profiling","volume":"11","author":"Bowes","year":"2012","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1016\/j.bmcl.2019.06.047_b0075","unstructured":"Pharmacology Review(s). Rilpivirine, Edurant. FDA Approval package for NDA 202022; 2011."},{"key":"10.1016\/j.bmcl.2019.06.047_b0080","doi-asserted-by":"crossref","first-page":"8582","DOI":"10.1021\/jm201134m","article-title":"Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents","volume":"54","author":"Bollini","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.06.047_b0085","doi-asserted-by":"crossref","first-page":"E802","DOI":"10.1073\/pnas.1717932115","article-title":"From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection","volume":"115","author":"Kudalkar","year":"2018","journal-title":"PNAS"},{"key":"10.1016\/j.bmcl.2019.06.047_b0090","doi-asserted-by":"crossref","first-page":"9725","DOI":"10.1073\/pnas.1711463114","article-title":"Covalent inhibitors for eradication of drug-resistant HIV-1 reverse transcriptase: From design to protein crystallography","volume":"114","author":"Chan","year":"2017","journal-title":"PNAS"},{"key":"10.1016\/j.bmcl.2019.06.047_b0095","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/cbdd.12266","article-title":"Structure-based evaluation of C5 derivatives in the catechol diether series targeting HIV-1 reverse transcriptase","volume":"83","author":"Frey","year":"2014","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.bmcl.2019.06.047_b0100","doi-asserted-by":"crossref","first-page":"16705","DOI":"10.1021\/ja408917n","article-title":"Picomolar inhibitors of HIV reverse transcriptase featuring bicyclic replacement of a cyanovinylphenyl group","volume":"135","author":"Lee","year":"2013","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmcl.2019.06.047_b0105","doi-asserted-by":"crossref","first-page":"11300","DOI":"10.1128\/JVI.05584-11","article-title":"Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I\/V mutations","volume":"85","author":"Xu","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.bmcl.2019.06.047_b0110","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1006\/abio.1997.2177","article-title":"Characterization of PicoGreen reagent and development of a fluorescence-based solution assay for double-stranded DNA quantitation","volume":"249","author":"Singer","year":"1997","journal-title":"Anal Biochem"},{"key":"10.1016\/j.bmcl.2019.06.047_b0115","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nprot.2007.517","article-title":"Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later","volume":"3","author":"Pannecouque","year":"2008","journal-title":"Nat Protoc"},{"key":"10.1016\/j.bmcl.2019.06.047_b0120","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1073\/pnas.0711209105","article-title":"High-resolution structures of HIV-1 reverse transcriptase\/TMC278 complexes: strategic flexibility explains potency against resistance mutations","volume":"105","author":"Das","year":"2008","journal-title":"PNAS"},{"key":"10.1016\/j.bmcl.2019.06.047_b0125","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.1016\/j.bmcl.2013.06.093","article-title":"Extension into the entrance channel of HIV-1 reverse transcriptase\u2013crystallography and enhanced solubility","volume":"23","author":"Bollini","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2019.06.047_b0130","doi-asserted-by":"crossref","first-page":"19501","DOI":"10.1021\/ja3092642","article-title":"Crystal structures of HIV-1 reverse transcriptase with picomolar inhibitors reveal key interactions for drug design","volume":"134","author":"Frey","year":"2012","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmcl.2019.06.047_b0135","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1016\/j.bmcl.2010.05.040","article-title":"Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses","volume":"20","author":"Kertesz","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2019.06.047_b0140","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1046\/j.1432-1327.2002.02811.x","article-title":"Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant","volume":"269","author":"Lindberg","year":"2002","journal-title":"Eur J Biochem FEBS"},{"key":"10.1016\/j.bmcl.2019.06.047_b0145","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1021\/jm501908a","article-title":"Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target hiv reverse transcriptase variants","volume":"58","author":"Frey","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.06.047_b0150","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/jps.22242","article-title":"Physicochemical properties of the amorphous drug, cast films, and spray dried powders to predict formulation probability of success for solid dispersions: etravirine","volume":"100","author":"Weuts","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.bmcl.2019.06.047_b0155","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1021\/jm8004493","article-title":"Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors","volume":"51","author":"Ren","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.06.047_b0160","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1128\/AAC.02403-13","article-title":"In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor","volume":"58","author":"Lai","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2019.06.047_b0165","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.bmcl.2013.12.070","article-title":"Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses","volume":"24","author":"Cote","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2019.06.047_b0170","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1124\/mol.116.107755","article-title":"Structural and preclinical studies of computationally designed non-nucleoside reverse transcriptase inhibitors for treating HIV infection","volume":"91","author":"Kudalkar","year":"2017","journal-title":"Mol Pharmacol"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X19304299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X19304299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:29:36Z","timestamp":1760772576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X19304299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":34,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0960894X19304299"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2019.06.047","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular and cellular studies evaluating a potent 2-cyanoindolizine catechol diether NNRTI targeting wildtype and Y181C mutant HIV-1 reverse transcriptase","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2019.06.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}